Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): Use in prophylaxis for pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ

Clinical Infectious Diseases

Volumn 20, Issue 4, 1995, Pages 849-853

  Gluckstein, Daniel ^a   Ruskin, Joel ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE; DIPHENHYDRAMINE; IBUPROFEN; PENTAMIDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM; ZIDOVUDINE;

ADULT; ARTICLE; CHILL; CLINICAL ARTICLE; DESENSITIZATION; DOSE RESPONSE; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MIXTURE; DRUG SAFETY; DYSESTHESIA; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ORAL DRUG ADMINISTRATION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FOLLOW-UP STUDIES; HUMAN; MALE; PNEUMONIA, PNEUMOCYSTIS CARINII; RETROSPECTIVE STUDIES; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0028918268     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/20.4.849     Document Type: Article

References (46)

1. Masur H, Ognibene FP, Yarchoan R, et al. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 1989; 1 i 1:223-31.
2. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990;322:161-5.
3. Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfameth oxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185-9.
4. Ruskin J, LaRiviere M. Low-dose co-trimoxazole for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus disease. Lancet 1991;337:468-71.
5. Stein DS, Stevens RC, T erry D, et al. Use of low-dose trimethoprim-sul-famethoxazole thrice weekly for primary and secondary prophylaxis of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1991; 35:1705-9.
6. Wormser GP, Horowitz HW, Duncanson FP, et al. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. Arch Intern Med 1991; 151:688-92.
7. MacGregor RR, Morgan AS, Graziani AL, et al. Efficacy and tolerance of intermittent versus daily cotrimoxazole for PCP prophylaxis in HIV-positive patients. Am J Med 1992;92:227-9.
8. Schneider MME, Hoepelman AIM, Eeftinck Schattenkerk JK.M, et al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992;327:1836-41.
9. Hardy WD, Feinberg J, Finkelstein DM, et al. A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: AIDS clinical trials group protocol 021. N Engl J Med 1992;327:1842-8.
10. Freedberg KA, Tosteson ANA, Cohen CJ, Cotton DJ. Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991;4:521-31.
11. Castellano AR, Nettleman MD. Cost and benefit of secondary prophylaxis for Pneumocystis carinii pneumonia. JAMA 1991;266:820-4.
12. Carr A, Tindall B, Brew BJ, et al. Low-dose trimethoprim-sulfamethox-azole prophylaxis for toxoplasmic encephalitis in patients with AIDS. Ann Intern Med 1992; 117:106-11.
13. Centers for Disease Control. Recommendations for prophylaxis against Pneumocystis carinii pneumonia for adults and adolescents infected with HIV. MMWR 1992;41 (RR-4): 1-12.
14. Small CB, Harris CA, Friedland GH, Klein RS. The treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Arch Intern Med 1985; 145:837-40.
15. Wharton JM, Coleman DL. Wofsy CB, et al. Trimethoprim-sulfameth-oxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective randomized trial. Ann Intern Med 1986; 105:37-44.
16. Wofsy CB. Use of trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonitis in patients with acquired immunodeficiency syndrome. Rev Infect Dis 1987;9(suppl 2):S184-94.
17. Medina I, Mills J, Leoung G, et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990;323:776-82.
18. Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med 1993;328:1670-4.
19. Torres RA, Barr M, Thorn M, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993; 95: 573-83.
20. Gluckstein D, Ruskin J, Nielsen D. Oral desensitization to trimetho prim/sulfamethoxazole (T/S): utility in T/S prophylaxis of Pneumocystis carinii pneumonia [abstract no 7176], In: Program and ab. stracts of the 4th International Conference on AIDS (Stockholm). 1988.
21. Hughes TE, Almgren JD, McGuffin RW, Omoto RJ. Co-trimoxazole desensitization in bone marrow transplantation [letter], Ann Intern Med 1986;105:148.
22. Finegold I. Oral desensitization to trimethoprim-sulfamethoxazole in a patient with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1986;78:905-8.
23. Smith RM, Iwamoto GK, Richerson HB, Flaherty JP. Trimethoprim-sulfamethoxazole desensitization in the acquired immunodeficiency syndrome [letter], Ann Intern Med 1987; 106:335.
24. Greenberger PA, Patterson R. Management of drug allergy in patients with acquired immunodeficiency syndrome. J Allergy Clin Immunol 1987;79:484-8.
25. Papakonstantinou G, Fiiessl H, Hehlmann R. Trimethoprim-sulfa methoxazole desensitization in AIDS. Klin Wochenschr 1988; 66:351-3.
26. Papakonstantinou G, Fiiessl H, Matuschke A, Hehlmann R. Therapy of Pneumocystis carinii pneumonia after trimethoprim-sulfamethoxazole desensitization. Klin Wochenschr 1989;67:316.
27. White MV, Haddad ZH, Brunner E, Sainz C. Desensitization to tri methoprim sulfamethoxazole in patients with acquired immune deficiency syndrome and Pneumocystis carinii pneumonia. Ann Allergy 1989;62:177-9.
28. Torgovnick J, Arsura E. Desensitization to sulfonamides in patients with HIV infection [letter]. Am J Med 1990;88:548-9.
29. Kreuz W, Giingor T, Lotz C, Funk M, Kornhuber B. “Treating through” hypersensitivity to co-trimoxazole in children with HIV infection [letter]. Lancet 1990;336:508-9.
30. Raphael SA, Lischner HW, Gregonis SW. Prophylaxis against Pneumocystis carinii pneumonia in children with HIV [letter], JAMA 1991;266:1078-9.
31. Kletzel M, Beck S, Elser J, Shock N, Burks W. Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991; 145:1428-9.
32. Nguyen MT, Wallace MR, Weiss PJ, Bone WD, Kennedy CA. Trimethoprim-sulfamethoxazole (TMP-SMX) desensitization in HIV patients with previously documented TMP-SMX intolerance [abstract 193]. In: Abstracts of the 1993 Infectious Diseases Society of America annual meeting. Clin Infect Dis 1993; 17:563.
33. Shafer RW, Seitzman PA, Tapper ML. Successful prophylaxis of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in AIDS patients with previous allergic reactions. J Acquir Immune Defic Syndr 1989;2:389-93.
34. Gibbons RB, Lindauer JA. Successful treatment of Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole in hypersensitive AIDS patients [letter], JAMA 1985;253:1259-60.
35. Sattler FR, Cowan R, Nielsen DM, Ruskin J. Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: a prospective, noncrossover study. Ann Intern Med 1988; 109:280-7.
36. Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992; 152:523-8.
37. Carr A, Tindall B, Penny R, Cooper DA. Trimethoprim-sulphamethox-azole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992;6:165-71.
38. Kennedy CA, Pimentel JA, Lewis DE, Anderson MD, Weiss PJ, Oldfield EC III. Crossover of human immunodeficiency virus-infected patients from aerosolized pentamidine to trimethoprim-sulfamethoxazole: lack of hematologic toxicity and relationship of side effects to CD4+ lymphocyte count. J Infect Dis 1993; 168:314-7.
39. Kelly JW, Dooley DP, Lattuada CP, Smith CE. A severe, unusual reaction to trimethoprim-sulfamethoxazole in patients infected with human immunodeficiency virus. Clin Infect Dis 1992; 14:1034-9.
40. Silvestri RC, Jensen WA, Zibrak JD, Alexander RC, Rose RM. Pulmonary infiltrates and hypoxemia in patients with the acquired immunodeficiency syndrome re-exposed to trimethoprim-sulfamethoxazole. Am Rev Respir Dis 1987;136:1003-4.
41. Arnold PA, Guglielmo BJ, Hollander H. Severe hypersensitivity reaction upon rechallenge with trimethoprim-sulfamethoxazole in a patient with AIDS. Drug Intell Clin Pharm 1988;22:43-5.
42. Ulstad DR, Ampel NM, Shon BY, Galgiani JN, Cutcher AB. Reaction after re-exposure to trimethoprim-sulfamethoxazole [letter]. Chest 1989;95:937-8.
43. Johnson MP, Goodwin SD, Shands JW Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: case reports and literature review. Pharmacotherapy 1990; 10:413-6.
44. Martin GJ, Paparello SF, Decker CF. A severe systemic reaction to trimethoprim-sulfamethoxazole in a patient infected with the human immunodeficiency virus [letter], Clin Infect Dis 1993; 16:175-6.
45. Marinac JS, Stanford JF. A severe hypersensitive reaction to trimetho prim-sulfamethoxazole in a patient infected with human immunodeficiency virus [letter], Clin Infect Dis 1993; 16:178-9.
46. Nguyen B-Y, Landucci DL, Cunnion RE, Yarchoan R, Walker RE. A case of hyperdynamic shock caused by trimethoprim-sulfamethoxazole in which no tumor necrosis factor or features of anaphylaxis were detected. Clin Infect Dis 1993; 17:885-7.